Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients.

This is a multicenter, prospective, randomized controlled, phase II study. The primary objective is to evaluate the effect of endocrine therapy modification (switching from a 3-month to a 1-month GnRHa) versus continuation of the 3-month GnRHa on E2 control at 3 months in young patients with hormone receptor-positive breast cancer and iOFS.

NCT Number	NCT07610733
Lead Sponsor	Fudan University
Conditions	Breast Cancer
Enrollment	100 participants
Start Date	2026-06-01
Primary Completion	2027-09-01 (estimated)
Study Completion	2030-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-28